Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 18;35(11):e351102.
doi: 10.1590/ACB351102. eCollection 2020.

The effect of activated protein C in the experimental disseminated intravascular coagulation model formed by lipopolysaccharide infusion

Abdullah Öahin  1 , Nazmi Özer  2
Affiliations

The effect of activated protein C in the experimental disseminated intravascular coagulation model formed by lipopolysaccharide infusion

Abdullah Öahin et al. Acta Cir Bras. .

Abstract

Purpose: In this experimental study, activated protein C (APC), which has anticoagulant, antithrombotic, profibrinolytic, anti-inflammatory and antiapoptotic properties, was used to prevent coagulopathy in a disseminated intravascular coagulation (DIC) model formatted with lipopolysaccharide (LPS) infusion.

Methods: Twenty-five Wistar albino rats weighting 280 - 320 g each were used. They were randomly divided into three groups: sham, control and study groups. To sham group (n = 5), only normal saline was infused. To control (n = 10) and study groups (n = 10), 30 mg/kg LPS was infused for 4 h from femoral vein. After LPS infusion, 100 µg/kg recombinant APC was given during 4 h in study group. Eight hours later, blood samples were taken from abdominal aorta and the animals sacrificed. From these samples, platelet, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen and D-dimer levels were studied.

Results: Platelet counts and fibrinogen levels were significantly lower in control and study groups than sham group (p < 0.05). The PT, aPTT and D-dimer levels were significantly higher in control and study groups than in sham group (p < 0.05). When comparing control and study groups, platelet counts were not statistically different (p = 0.36). However, the difference of the fibrinogen levels was significant between these groups (p = 0.0001). While PT and aPTT were longer in the study group compared to the control group (p < 0.05), D-dimer levels were lower in the study group than in control (p = 0.0001).

Conclusion: Use of APC can prevent hypercoagulation and consumption coagulopathy in the DIC as a result of correcting hematological parameters other than prolongation of coagulation time.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none

Figures

Figure 1
Figure 1. (a) Femoral vein catheterization, (b) Injection of lipopolysaccharide from the femoral vein, (c) Taking blood sample from the aorta.
Figure 2
Figure 2. Comparison of the groups according to thrombocyte (platelet) counts.
Figure 3
Figure 3. Comparison of the groups accoring to activated Partial Thromboplastin Time (aPTT).
Figure 4
Figure 4. Comparison of groups by prothrombin time (PT).
Figure 5
Figure 5. Comparison of the groups according to activated fibrinogen levels.
Figure 6
Figure 6. Comparison of the groups according to activated fibrinogen levels.
See this image and copyright information in PMC

References

    1. Levi M, Sivapalaratnam S. Disseminated intravascular coagulation: an update on pathogenesis and diagnosis. Expert Rev Hematol. 2018;11(8):663–672. doi: 10.1080/17474086.2018.1500173. - DOI - PubMed
    1. Thachil J. Disseminated intravascular coagulation - new pathophysiological concepts and impact on management. Expert Rev Hematol. 2016;9(8):803–814. doi: 10.1080/17474086.2016.1203250. - DOI - PubMed
    1. Levi M. Pathogenesis and diagnosis of disseminated intravascular coagulation. Int J Lab Hematol. 2018;40(Suppl 1):15–20. doi: 10.1111/ijlh.12830. - DOI - PubMed
    1. Dhainaut JF, Yan SB, Claessens YE. Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis. Crit Care Med. 2004;32(5 Suppl):S194–S201. doi: 10.1097/01.ccm.0000128035.64448.45. - DOI - PubMed
    1. Amiral J, Seghatchian J. Revisiting the activated protein C-protein S-thrombomodulin ternary pathway: Impact of new understanding on its laboratory investigation. Transfus Apher Sci. 2019;58(4):538–544. doi: 10.1016/j.transci.2019.06.008. - DOI - PubMed